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Introduction {#sec001}
============

Chronic Kidney Disease (CKD) according to KDIGO (Kidney Disease: Improving Global Outcomes) guidelines requires that a measured glomerular filtration rate abnormality or evidence of kidney damage (e.g. albuminuria), or both, be present for a minimum of three months \[[@pone.0230493.ref001]\]. End stage renal disease (ESRD) requires renal replacement therapy (dialysis or kidney transplantation). Phosphate retention in CKD and ESRD is a major driver of endothelial damage, and cardiovascular morbidity and mortality \[[@pone.0230493.ref002]\]. A disturbed phosphate homeostasis is closely associated with soft tissue calcifications and accelerated aging \[[@pone.0230493.ref003]\]. We and others have suggested that calciprotein particles (CPP), colloidal blood-borne particles containing calcium phosphate and plasma proteins, e.g. the hepatic glycoprotein fetuin-A and albumin, stabilize extracellular fluids supersaturated with calcium and phosphate, and are associated with CKD \[[@pone.0230493.ref004]--[@pone.0230493.ref012]\]. In CKD, hyperphosphatemia is the driving force of CPP formation \[[@pone.0230493.ref013]--[@pone.0230493.ref017]\], but calcium overload seems to be causing inflammation-associated tissue damage and calcification. CPP carry excess calcium and phosphate as colloids stabilized by plasma-derived "mineral chaperone proteins" \[[@pone.0230493.ref018]\]. In CKD, CPP are continuously formed, yet insufficiently cleared, and therefore seem to be the "culprit of phosphorous woes" \[[@pone.0230493.ref017]\]. Because serum phosphate is a well-established risk factor for CKD associated morbidity \[[@pone.0230493.ref003], [@pone.0230493.ref013]--[@pone.0230493.ref015]\], serum phosphate reduction is a major goal of dialysis apart from body fluid reduction and uremic toxin removal. However, the simple measurement of serum phosphate often does not correlate well with clinical outcome in patient cohorts, because it fails to detect the contribution of low and high molecular weight inhibitors of phosphate crystallization. We developed a functional test measuring the overall calcification propensity in blood serum or plasma \[[@pone.0230493.ref019]\]. This so called T50 test measures the time between mixing blood serum with calcium and phosphate, and the time at which colloidal mineral complexes called primary CPP have undergone half-maximum transformation to larger secondary CPP, hence the name T50 test.

The CPP transformation is detected as a sharp increase in turbidity of a test solution, which is measured by light scattering in a nephelometer. Serum samples of healthy subjects transform later than serum samples from dialysis patients. The test has been widely used to assess patient cohorts for prognosis and outcome including CKD patients \[[@pone.0230493.ref020], [@pone.0230493.ref021]\], hemodialysis patients \[[@pone.0230493.ref022], [@pone.0230493.ref023]\], and kidney transplant patients \[[@pone.0230493.ref024], [@pone.0230493.ref025]\]. The T50 test is a functional global assay measuring CPP transformation, which is influenced by low molecular regulators of mineralization like pyrophosphate and magnesium as well as large molecular weight plasma-derived mineral chaperone proteins \[[@pone.0230493.ref018]\]. Thus, CPP reflect better than serum phosphate "the culprit of phosphorous woes", i.e. phosphate toxicity \[[@pone.0230493.ref017], [@pone.0230493.ref026]\], especially if they are formed in excess or insufficiently cleared.

Variations of the original T50 test \[[@pone.0230493.ref027]\] have been employed for cross-sectional studies and for drug development \[[@pone.0230493.ref007], [@pone.0230493.ref028], [@pone.0230493.ref029]\]. The nephelometer-based assay requires measurement times of up to 600 minutes, rendering the test unsuitable for bed side measurements. Yet a rapid functional T50 test is highly desirable for point-of-care or even in-line measurements. Studying the kinetics of CPP formation and ripening we showed that particle ripening follows Arrhenius law \[[@pone.0230493.ref030]\]. Therfor the reaction kinetics should be logarithmically accelerated with increased temperature. In addition, we attempted to minimize test volumes to avoid reagent mixing and thermal issues to ultimately allow integration of the test in-line into existing dialysis equipment. Here we report that running the T50 test increasing the assay temperature from 37°C to 75°C reduced the T50 test time 36-fold from 381 ± 10 min at 37°C to 10.5 ± 0.3 min at 75°C. Incorporating sputtered micro mirrors into the chip design increased the effective light path length, and improved signal-to-noise ratio 9-fold.

Material and methods {#sec002}
====================

Microfluidic chip fabrication {#sec003}
-----------------------------

An aluminium replica tool for embossing the chip base was micro milled with a computer controlled micro mill (model M7 HP, Datron, Mühltal, Germany). The base of the microfluidic chip was fabricated by ultrasonic hot embossing a stack of a 4 mm thick polycarbonate sheet (Arla Plast AB, Borensberg, Sweden) and a 125 μm thick polycarbonate foil (Rachow Kunststoff-Folien, Hamburg, Germany) using an ultrasonic welding machine (2000IW, Branson, Danbury, USA) as described \[[@pone.0230493.ref031], [@pone.0230493.ref032]\]. The base of the chip containing the measuring cell and microfluidic channels was ultrasonic hot embossed and 0.5 mm thick polycarbonate sheet was ultrasonically welded as a lid on top using the parameters listed in [Table 1](#pone.0230493.t001){ref-type="table"}.

10.1371/journal.pone.0230493.t001

###### Parameters of ultrasonic processing.

![](pone.0230493.t001){#pone.0230493.t001g}

  Process                             Hot embossing   Welding
  ----------------------------------- --------------- ---------
  **Force threshold \[N\]**           290             170
  **Amplitude of vibration \[μm\]**   27.2            24
  **Force during vibrations \[N\]**   912             450
  **Duration of vibrations \[s\]**    1.35            0.28
  **Holding time \[s\]**              3               1.6
  **Force during holding \[N\]**      912             450

The aluminium replica tool containing microfluidic channels and energy directors was micro milled. For the integration of mirrors into the measuring cuvette, the edges of the cuvette wall were sloped using a 45° angle milling head. Mirrors were generated by sputtering a 170 nm layer of titanium onto the microchips after ultrasonic hot embossing and before ultrasonic welding the lid foil. To avoid overheating of the polymer, the titanium was sputtered in 6 steps, 10 s each, allowing intermittent intervals of 30 s for cooldown. An AZ 400 sputtering machine (Leybold Heraeus, Köln, Germany) was used at an argon flow of 100 sccm and a supply power of 400 W.

Chip holder with Peltier element and temperature control {#sec004}
--------------------------------------------------------

The chips were clamped into a holder. The chip temperature was adjusted by a Peltier element \[[@pone.0230493.ref032]\]. The ambient temperature and the Peltier element temperature were measured with PT1000 sensors using a LabVIEW interface program. Pre-mixed reaction fluid was injected by a syringe pump (KR Analytical, Cheshire, United Kingdom).

Human serum samples {#sec005}
-------------------

The use of human serum samples was approved by the local Ethical Board of RWTH Aachen University Clinics Ethical Board ([www.medizin.rwth-aachen.de/EK](http://www.medizin.rwth-aachen.de/EK); EK 300/14). Samples were from a biobank. Serum samples were from adult healthy donors and from dialysis patients who gave written informed consent. All samples used in this study were analyzed anonymously. Pooled anonymized serum samples were employed for the replica measurements shown in [Fig 6](#pone.0230493.g006){ref-type="fig"}.

Reaction mixture and setup {#sec006}
--------------------------

The reaction mixture was prepared at room temperature in 1.5 ml reaction tubes by thoroughly mixing 0.4 mL pooled human serum and 0.35 mL of a 28.6 mmol CaCl~2~ solution. Next, 0.25 mL of a 24 mmol Na~2~HPO~4~ solution was added and again thoroughly vortexed. Solutes and final concentrations were as published \[[@pone.0230493.ref033]\]. The reaction mixture was immediately injected into the inlet of the microfluidic chip using a Luer lock syringe attached to the inlet of the chip. The chip was clamped to the holder, illuminated with a laser diode (IMM-1255FB-635-1-E-G-L, IMM Photonics GmbH, Unterschleißheim, Deutschland) at 635 nm (Laser diode, 3.4×0.8 mm^2^ beam cross section, 20 mm focus length), and turbidity in the light path was continuously monitored by a light dependent resistor (GM5528, Φ 5 Series, Wodeyijia Technology, Shenzhen, China).

A LabVIEW script controlled both the temperature and the voltage measurement at the light dependent resistor (LDR). All recorded data were stored in a log file that was further processed with Microsoft Excel.

Results and discussion {#sec007}
======================

Microfluidic chip fabrication {#sec008}
-----------------------------

The polymer chips were manufactured by ultrasonic hot embossing and welding of polycarbonate. [Fig 1](#pone.0230493.g001){ref-type="fig"} shows the typical workflow of microfluidic chip production. During ultrasonic hot embossing, ultrasonic vibrations are generated by a sonotrode generating friction heat between the polymer base plate of the chip and a polymer foil, which was placed against the embossing aluminium tool ([Fig 1A](#pone.0230493.g001){ref-type="fig"}). The friction heat generated by the vibrations at the interface of tool and polymer foil and especially between polymer foil and polymer base plate melted the polymer ([Fig 1B](#pone.0230493.g001){ref-type="fig"}). The compressive force of the anvil replicated the micro structures of the aluminium tool. After a few seconds cooldown time the solidified chip base was demoulded ([Fig 1C](#pone.0230493.g001){ref-type="fig"}). The two layers of polymer (base plate and foil) were fused into a single piece of polymer. [Fig 1D and 1E](#pone.0230493.g001){ref-type="fig"} illustrate how the finished chip base was covered using a polymer lid, which was sealed around the edges of the chip microchannels along the energy directors. [Fig 1F](#pone.0230493.g001){ref-type="fig"} illustrates the release of the finished microchip. [Fig 1G](#pone.0230493.g001){ref-type="fig"} shows the actual micro machined aluminium tool used for embossing chips for transmitted laser light measurements. [Fig 1I](#pone.0230493.g001){ref-type="fig"} shows a matching polymer chip base plate with machined recesses, into which excess polymer can overflow during hot embossing. [Fig 1H](#pone.0230493.g001){ref-type="fig"} shows a finished hot embossed chip with the cover lid, but without connectors.

![Fabrication of a microchip by ultrasonic hot embossing and welding.\
**A,** Polymer plate and foil are placed between tool and sonotrode; **B,** The sonotrode presses the polymer layers onto the tool and generates friction heat, the polymer layers are welded together to form a micro patterned chip base; **C,** After cooling down and solidifying, the chip base is removed from the tool; **D,** The micro patterned plate and a polymer lid are placed onto the anvil; **E,** The sonotrode welds both parts by friction heat; **F,** The sealed microfluidic chip is removed from the machine; **G,** Aluminum replica tool for two microfluidic chambers fabricated by micro milling; **I,** Polymer base plate with machined recesses for excess molten polymer; **H,** Ultrasonically hot embossed chip with cover lid.](pone.0230493.g001){#pone.0230493.g001}

For embossing large grooves into the polymer, e.g. a sample cell with a depth of 1 mm and an area of 35 mm^2^, a recess was machined into the polymer base plates before ultrasonic hot embossing. Thus, less molten polymer needed to be displaced and less vibration energy was required.

Ultrasonic movement of the polymer base plate against the polymer foil generated friction at the interface of polymer foil and tool, and also between polymer foil and base plate thus enhancing heat generation inside the polymer stack. As an added advantage, the melt between the polymer foil and the polymer base plate was thermally insulated from the cool and thermally conductive tool, facilitating polymer flow.

The microfluidic chips manufactured for this work were embossed using a combination of a 125 μm thick polycarbonate foil and a 4 mm thick polycarbonate base plate. The resulting chips were covered with a 0.5 mm thick polycarbonate lid. Ultrasonic welding was similar to embossing the base plate, but reduced vibration amplitude and force were selected to avoid damaging the micro channels. Instead, only the so-called energy directors melted as intended ([Fig 1D--1F](#pone.0230493.g001){ref-type="fig"}). Fabrication parameters are listed in [Table 1](#pone.0230493.t001){ref-type="table"}.

[Fig 2](#pone.0230493.g002){ref-type="fig"} shows a schematic of the microfluidic chip design next to the finished hot embossed real chips. [Fig 2A](#pone.0230493.g002){ref-type="fig"} represents a chip with translucent cuvette for transmitted laser light measurements.

![Microfluidic polymer chips for calcium phosphate crystallization analyses produced by ultrasonic hot embossing and welding.\
Each chip contains two cuvettes allowing two analyses in one chip. The drawing of the cross-sections is not to scale. **A,** A two chamber chip design with embossed fluidic channels and cuvette, a polymer foil lid designed for transmitted laser light measurements. **B,** An improved design including sputtered titanium mirrors on either side of the cuvette, and a diffusor in front of the detector, effectively increasing the measuring path length and distributing the laser light transmitted through the cuvette over the entire surface of the light dependent resistor, LDR.](pone.0230493.g002){#pone.0230493.g002}

[Fig 2B](#pone.0230493.g002){ref-type="fig"} shows an improved design featuring mirrored cuvette surfaces for reflected laser light measurement. This was achieved by inserting mirrors tilted by 45° relative to the bottom of the cuvette. In this chip, the laser light was reflected twice and its path through the sample solution was thus extended to 10 mm from 1 mm, the vertical dimension of the cuvette. Due to the longer path, more light was absorbed by the reaction mixture and a stronger signal was recorded by the LDR when primary CPP transformed into secondary CPP.

Data acquisition and processing {#sec009}
-------------------------------

The light sensitive detector had its highest sensitivity at low luminosity. Therefore, the laser diode was driven at a comparatively small electrical current of 10 mA. In the improved chip design shown in [Fig 2B](#pone.0230493.g002){ref-type="fig"}, a diffusor made of polypropylene (PP) was placed in front of the LDR, further reducing the light intensity per area of the LDR.

[Fig 3A](#pone.0230493.g003){ref-type="fig"} shows a plot of the light intensity as a function of time measured with the light dependent sensor and the microchip shown in [Fig 2A](#pone.0230493.g002){ref-type="fig"}. The curve was smoothed by plotting the sliding average of the voltages measured 100 s before and 100 s after each data point. The time range of 100 s was chosen because it yielded a smoothed curve without flattening the overall curve.

![Determination of T50-value by a parabola fit to the first order derivative of light intensity transmitted through the sample.\
**A,** The red line represents the smoothed light intensity plotted against time. **B,** The blue line corresponds to the first order derivative of the light intensities. T50 corresponds to the vertex of the parabola determined by a χ^2^-fit, which is shown as an orange dotted line.](pone.0230493.g003){#pone.0230493.g003}

In an alternative plot shown in [Fig 4B](#pone.0230493.g004){ref-type="fig"}, the difference of the average of voltages 200 s after each time point and the average of the 200 s before this time point were plotted against time. This representation is similar to the first derivative of the turbidity. The maximum of the derivative corresponds to the time of the maximum slope of the turbidity curve shown in [Fig 3A](#pone.0230493.g003){ref-type="fig"} and represents the T50 time. The curve peak was determined by a χ^2^-fit resulting in the parabola plotted as an orange dotted line in [Fig 3B](#pone.0230493.g003){ref-type="fig"}. In this representation, T50 corresponds to the vertex of the parabola determined by the χ^2^-fit. This way, the maximum slope of the curve in [Fig 3A](#pone.0230493.g003){ref-type="fig"} is not based on a single data point subject to scatter but includes all the measured turbidity changes in its vicinity, resulting in better accuracy.

![T50 measurement with and without mirrors in the microchip.\
T50 measurements of identical serum samples were taken at 65°C. **A,** Direct light dependent resistor (LDR) output, **B,** sliding average LDR output results in curve smoothing. Mirrors in the microchip increased the effective length of the measuring path through the sample cell from 1mm to 10 mm, reduced noise and increased the overall voltage step.](pone.0230493.g004){#pone.0230493.g004}

[Fig 4](#pone.0230493.g004){ref-type="fig"} shows T50 measurements taken with identical serum at 65°C with and without mirrors built into the chip (blue line and red line, respectively). The integration of mirrors increased the effective length of the light path from 1 mm to roughly 10 mm as illustrated in [Fig 2](#pone.0230493.g002){ref-type="fig"}. The voltage increase used to determine the T50 value was 1.8 V and 0.2 V with and without mirrors, respectively, demonstrating a 9-fold increase in sensitivity.

[Fig 4A](#pone.0230493.g004){ref-type="fig"} shows raw data with spikes, and [Fig 4B](#pone.0230493.g004){ref-type="fig"} shows data representing the sliding average of 40 s before and after each time. Notably, both [Fig 4A](#pone.0230493.g004){ref-type="fig"} and [Fig 4B](#pone.0230493.g004){ref-type="fig"} show that the signal to noise ratio and the overall voltage step were much improved by inserting mirrors, resulting in an overall more robust determination of T50.

Results of the miniaturized calcification propensity test {#sec010}
---------------------------------------------------------

Human serum was mixed with calcium and phosphate, and the T50 times were measured at temperatures ranging from 60 to 85°C employing microchips with integrated mirrors. The change in turbidity due to the formation of secondary CPPs was detected as a function of time. Measurements at each temperature were done once with identical serum, each with a fresh chip.

[Fig 5](#pone.0230493.g005){ref-type="fig"} shows that increasing the assay temperature strongly reduced T50 time. At 60°C a swift increase in turbidity within the first 5 minutes suggested protein denaturation, which was followed by the typical sigmoidal curve indicating transformation of primary CPP into secondary CPP at T50 = 34 minutes. Increasing the assay temperature beyond 60°C cut off the initial protein denaturation signal, and further reduced the T50 times to 13, 10, 3.8, 2 and 0.5 minutes at temperatures 65, 70, 75, 80 and 85°C, respectively. Raising the temperature beyond 75°C reduced reproducibility at even the slightest variations in pipetting and handling. Thus, we choose 75°C for a comparison of chip assay-derived T50 values with nephelometer assay-derived T50 values ([Fig 6](#pone.0230493.g006){ref-type="fig"}).

![T50 chip tests at elevated temperature.\
Curves are staggered along the y-axis for clarity.](pone.0230493.g005){#pone.0230493.g005}

![Serum T50 values derived from chip measurements at 75°C compared to nephelometer measurements at 37°C.\
The error bars denote the standard errors of 15 and 5 independent replicate measurements in chip (75°C) and nephelometer assay (37°C), respectively, in five human serum pools covering the entire T50 range observed in published clinical studies.](pone.0230493.g006){#pone.0230493.g006}

All nephelometer measurements were repeated 5-fold, and every chip-based measurement was repeated 15-fold. The mean coefficient of variation (standard deviation divided by mean value) derived from microchip measurements (5.7% in the average of all measurements) was smaller than the one derived from nephelometer measurements (7.9%) suggesting excellent reproducibility of both chip manufacturing and test performance. [Fig 6](#pone.0230493.g006){ref-type="fig"} shows linear correlation (R^2^ = 0.9892) of nephelometer and chip-derived T50 values. The close correlation of both measurement routines indicates that the T50 values truly reflected the calcification propensity of the serum samples and not the rate of protein denaturation, which would have been expected to be identical in all sera, because they contained similar amounts of total protein. The measuring range presented in [Fig 6](#pone.0230493.g006){ref-type="fig"} covered previously published nephelometer-based T50 values including a reference range of healthy subjects (270 to 460 minutes), determined in 253 Swiss adults \[[@pone.0230493.ref021]\], values determined in 184 patients with CKD stages 3 to 4 (mean, 329 ± 95 minutes) \[[@pone.0230493.ref020]\] and in 2,785 patients undergoing hemodialysis (median, 212 \[10th-90th percentiles, 109--328\] minutes) \[[@pone.0230493.ref022]\].

Discussion and conclusions {#sec011}
==========================

We present a proof-of-principle miniaturized microfluidic T50 test format reporting overall calcification propensity in serum. The test has improved sensitivity and speed over the existing nephelometer-based test, which is the current gold standard. Before the chip-based test can be evaluated in large cohorts like the nephelometer-based test, an integrated cartridge holder with temperature and fluidics control unit, and data analysis must be developed. It should be noted in favour of the nephelometer-based test that automated reaction mixing was part of this test, but not of the chip-based test, and therefore the overall performance may not be strictly comparable. Nevertheless, our work indicates that the assay can be accelerated from hours to minutes by increasing the assay temperature, which is impossible using the established microtiter plate nephelometer-based assay. Short analysis times are advantageous in clinical settings when T50 measurements inform about the completeness of dialysis or about the influence of varying dialysis protocols or fluids. Importantly, the T50 times reflect the combined calcification propensity including solutes, activators and inhibitors as well as CPP, which might serve as mineralization nuclei that are poorly reflected by conventional phosphate monitoring. Recently, CPP and their precursors were directly end elegantly measured by two independent methods \[[@pone.0230493.ref006], [@pone.0230493.ref034]\]. These and similar methods may further refine the assessment of calcification propensity if miniaturized and accelerated like the chip-based T50 assay presented here.

The T50 acceleration was not linear, which might have been expected given that previous time-resolved small-angle X-ray and quantitative small-angle neutron scattering studies indicated first order CPP formation kinetics at 37°C \[[@pone.0230493.ref035]--[@pone.0230493.ref037]\]. We hypothesize that CPP formation and transformation of primary into secondary CPP at elevated temperature are more complex, because formation and dissolution of primary CPP, pH stability of the buffer system, and thermal denaturation of serum proteins will all influence the overall T50 time apart form the solute concentrations. These points require further physicochemical studies beyond the scope of this work. Nevertheless, we report close correlation of test temperature and T50 time up to 75°C. This was somewhat unexpected, because this temperature is above the denaturation temperature of many proteins. Published work shows however, that many serum proteins and complex protein solutions withstand high temperatures. Serum for cell culture is commonly heated to 56°C to inactivate complement proteins without affecting growth promoting and attachment factors. Proteins from thermophilic bacteria withstand temperatures above 100°C, e.g. the widely employed polymerase chain reaction enzyme Taq polymerase. Fetuin-A and albumin, two major protein components of CPP \[[@pone.0230493.ref011], [@pone.0230493.ref038]\] are also remarkably stable against thermal denaturation due to multiple internal disulphide bridges stabilizing their three-dimensional structure. Both proteins withstand temperatures beyond 70°C \[[@pone.0230493.ref039], [@pone.0230493.ref040]\] explaining why the chip-based T50 assay worked even at this high temperature. The proteins involved in CPP formation likely gain further stability to heat denaturation, because they are associated with a calcium phosphate solid phase.

Using a temperature controlled microfluidic polymer chip and serum samples from volunteers, we studied systematically the temperature dependent T50 assay acceleration and compared results with the established nephelometer test. We observed 36-fold acceleration and excellent correlation of results obtained from the established nephelometer test run at 37°C with results obtained with a temperature controlled microfluidic polymer chip operated at up to 75°C.

In conclusion, the speed and reproducibility of the T50 chip-based assay run at 75°C suggest that it may be suitable for rapid measurements, preferably in-line in a dialyser or in a portable microfluidic analytic device with the chip inserted as a disposable cartridge.

A pre-publication manuscript of this work was deposited as a printed abstract of the Biomedical Technology Conference BMT2018 \[[@pone.0230493.ref041]\].
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The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: In this manuscript, Bavendiek et al. present a newly designed microfluidic polymer chip which reduces times for measuring calcification propensity and may form a basis for future point of care tests. The most important part of this test is that measurement of calcification propensity can be achieved at much higher temperatures than the previous test thereby reducing measurement time from 600 to just a few minutes.

It is a engineering-orientated paper with detailed reports on the fabrication and optimization of the microchip.

Main comments:

\- What would be the benefit of a possible bedside test? Would there be changes in conducting dialysis or is calcification propensity rather a long-term parameter?

\- The introduction does not match the actual paper. Introduction handles kidney disease, hyperphosphatemia, morbidity, dialysis, clinical outcome etc, but the paper is an engineering-based approach. This should be adjusted to either more data on clinical use (e.g. adding a small clinical trial) or going all the way to an engineering paper.

\- The sera of 5 patients was used for validation of the test. But there is no data on the used test sera (Figure 7). Did the patients suffer from clinically relevant calcification? CAD?

\- Figure 1 seems to be redundant.

Reviewer \#2: Bavendiek et al demonstrated an improved temperature controlled T50 test format which reports Overall calcification propensity in serum.

While this is an important topic, there are some major limitations of this manuscript which might it challenging to follow. The authors should more emphasize the aim of the study, shorten the introduction and extend the discussion.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0230493.r003

Author response to Decision Letter 0

20 Dec 2019

Response To Reviewers

Our answer: We would like to thank all reviewers for their time and effort to improve the quality of our manuscript. We respond to their comments point-by-point.

Reviewers\' comments:

Reviewer\'s Responses to Questions

Comments to the Author

1\. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer \#1: Yes

Reviewer \#2: Yes

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

3\. Have the authors made all data underlying the findings in their manuscript fully available?

Reviewer \#1: Yes

Reviewer \#2: Yes

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

Reviewer \#1: Yes

Reviewer \#2: No

5\. Review Comments to the Author

Reviewer \#1: In this manuscript, Bavendiek et al. present a newly designed microfluidic polymer chip which reduces times for measuring calcification propensity and may form a basis for future point of care tests. The most important part of this test is that measurement of calcification propensity can be achieved at much higher temperatures than the previous test thereby reducing measurement time from 600 to just a few minutes.

It is a engineering-orientated paper with detailed reports on the fabrication and optimization of the microchip.

Our answer: We thank reviewer 1 for their appreciation of our work and the suggestions made in the comments.

Main comments:

\- What would be the benefit of a possible bedside test? Would there be changes in conducting dialysis or is calcification propensity rather a long-term parameter?

Our answer: The benefit of a bedside, or better still, an in-line test could be patient individualized dialysis. An example may be taken from work cited in ref. 30 showing the "The Effect of Increasing Dialysate Magnesium on Serum Calcification Propensity in Subjects with End Stage Kidney Disease". While such patient-individualized dialysis may still seem a long way off, an improved T50 test could be an important first step, because it better reflects the phosphorous woes (see ref 17) comprising phosphate, serum protein concentration, magnesium, pyrophosphate etc. than does serum phosphate alone.

\- The introduction does not match the actual paper. Introduction handles kidney disease, hyperphosphatemia, morbidity, dialysis, clinical outcome etc, but the paper is an engineering-based approach. This should be adjusted to either more data on clinical use (e.g. adding a small clinical trial) or going all the way to an engineering paper.

Our answer: We thank the reviewer for this suggestion. In the introduction we toned done on clinical findings and focused on the task at hand, technical improvement of the T50 assay.

\- The sera of 5 patients was used for validation of the test. But there is no data on the used test sera (Figure 7). Did the patients suffer from clinically relevant calcification? CAD?

Our answer: We have no information on the health status of the donors, because the samples were anonymized. To perform the repeat measurements shown in Fig 6 (was Fig 7) anonymized serum samples were blended to cover the range of published T50 studies, and to obtain sufficient amount of serum for repeat measurements. For clinical information we refer reviewer to the clinical studies employing the original T50 assay, some of which are cited.

\- Figure 1 seems to be redundant.

Our answer: we deleted Fig 1.

Reviewer \#2: Bavendiek et al demonstrated an improved temperature controlled T50 test format which reports Overall calcification propensity in serum.

While this is an important topic, there are some major limitations of this manuscript which might it challenging to follow. The authors should more emphasize the aim of the study, shorten the introduction and extend the discussion.

Our answer: We thank the reviewer for this suggestion. In the introduction we toned done on clinical findings and focused on the task at hand, technical improvement of the T50 assay. At this stage we would like to refrain from further discussion of this proof-of-principle study until we have completed a first clinical study using the novel chip-based T50 assay. We hope the reviewers can agree with this.

###### 

Submitted filename: Response To Reviewers.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0230493.r004
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© 2020 Marc W. Merx

2020

Marc W. Merx

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

27 Jan 2020

PONE-D-19-22409R1

Rapid calcification propensity testing in blood using a temperature controlled microfluidic polymer chip

PLOS ONE

Dear Prof Jahnen-Dechent,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process and quoted below.

We would appreciate receiving your revised manuscript by Mar 12 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Marc W. Merx, MD

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors present their revised manuscript on a newly designed microfluidic polymer chip which reduces times for measuring calcification propensity and may form a basis for future in-line tests. The most important part of this test is that measurement of calcification propensity can be achieved at much higher temperatures than the previous test thereby reducing measurement time from 600 to just a few minutes. It is an engineering-orientated paper with detailed reports on the fabrication and optimization of the microchip.

The manuscript has significantly improved due to the changes made in the introduction part.

Main comments:

\- We suggest to include one sentence/paragraph on the impact of reduced CPP measurements on dialysis quality in discussion.

Reviewer \#2: In the revised manuscript the authors have adequately addressed the reviewers\' comments. I would recommend to add one phrase about the expected clinical benefit/ relevance into the abstract.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0230493.r005

Author response to Decision Letter 1

28 Jan 2020

We thank both reviewers for their continued help and favorable judgement including their suggestion to comment on the potential clinical impact of this chip. We are happy to oblige. As before, we comment point-by-point quoting the original text. We hope the manuscript now meets the publication criteria.

Kind regards

Willi Jahnen-Dechent, on behalf of the authors

Comments to the Author

6\. Review Comments to the Author

Reviewer \#1: The authors present their revised manuscript on a newly designed microfluidic polymer chip which reduces times for measuring calcification propensity and may form a basis for future in-line tests. The most important part of this test is that measurement of calcification propensity can be achieved at much higher temperatures than the previous test thereby reducing measurement time from 600 to just a few minutes. It is an engineering-orientated paper with detailed reports on the fabrication and optimization of the microchip.

The manuscript has significantly improved due to the changes made in the introduction part.

Main comments:

\- We suggest to include one sentence/paragraph on the impact of reduced CPP measurements on dialysis quality in discussion.

Our comment: Following reviewer's suggestion we added a short paragraph to the discussion

"Short analysis times are advantageous in clinical settings when T50 measurements inform about the completeness of dialysis or about the influence of varying dialysis protocols or fluids. Importantly, the T50 times reflect the combined calcification propensity including solutes, activators and inhibitors as well as CPP, which might serve as mineralization nuclei that are poorly reflected by conventional phosphate monitoring. Recently, CPP and their precursors were directly end elegantly measured by two independent methods \[6, 34\]. These and similar methods may further refine the assessment of calcification propensity if miniaturized and accelerated like the chip-based T50 assay presented here."

Reviewer \#2: In the revised manuscript the authors have adequately addressed the reviewers\' comments. I would recommend to add one phrase about the expected clinical benefit/ relevance into the abstract.

Our comment: We added a sentence to the abstract

"The speed and reproducibility of the T50 chip-based assay run at 75°C suggest that it may be suitable for rapid measurements, preferably in-line in a dialyser or in a portable microfluidic analytic device with the chip inserted as a disposable cartridge."
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, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

3 Mar 2020

Rapid calcification propensity testing in blood using a temperature controlled microfluidic polymer chip

PONE-D-19-22409R2

Dear Dr. Jahnen-Dechent,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Marc W. Merx, MD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: (No Response)

Reviewer \#2: All reviewers\' comments are adequately adressed. I would suggest to accept this manuscript for publication.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

10.1371/journal.pone.0230493.r007
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5 Mar 2020

PONE-D-19-22409R2

Rapid calcification propensity testing in blood using a temperature controlled microfluidic polymer chip

Dear Dr. Jahnen-Dechent:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Dr. Marc W. Merx

Academic Editor

PLOS ONE
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